Black Rock Inc. Unicycive Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 51,837 shares of UNCY stock, worth $23,326. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,837Holding current value
$23,326% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding UNCY
# of Institutions
25Shares Held
26.6MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT8.56MShares$3.85 Million1.62% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.47MShares$2.01 Million0.27% of portfolio
-
Logos Global Management LP San Francisco, CA3.47MShares$1.56 Million0.16% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.82MShares$1.27 Million0.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.63MShares$1.18 Million0.02% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $6.77M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...